Price Action Don’t Lie: What’s Next for Adamas Pharmaceuticals Inc After Today’s Huge Increase?

Price Action Don't Lie: What's Next for Adamas Pharmaceuticals Inc After Today's Huge Increase?

The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) is a huge mover today! The stock increased 4.97% or $0.76 on November 23, hitting $16.05. About 118,054 shares traded hands. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has declined 14.76% since April 22, 2016 and is downtrending. It has underperformed by 20.17% the S&P500.
The move comes after 8 months positive chart setup for the $341.21 million company. It was reported on Nov, 24 by Barchart.com. We have $16.53 PT which if reached, will make NASDAQ:ADMS worth $10.24M more.

Analysts await Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to report earnings on February, 28. They expect $-0.86 earnings per share, down 48.28% or $0.28 from last year’s $-0.58 per share. After $-0.66 actual earnings per share reported by Adamas Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 30.30% negative EPS growth.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Ratings Coverage

Out of 7 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 6 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 86% are positive. Adamas Pharmaceuticals has been the topic of 12 analyst reports since August 7, 2015 according to StockzIntelligence Inc. On Tuesday, January 19 the stock rating was initiated by Cowen & Co with “Outperform”. The firm earned “Neutral” rating on Tuesday, January 19 by Mizuho. The stock has “Buy” rating given by Aegis Capital on Tuesday, September 22. The stock has “Market Outperform” rating given by JMP Securities on Friday, April 1. Noble Financial initiated it with “Buy” rating and $25 target price in Friday, June 17 report. The rating was maintained by Mizuho with “Buy” on Thursday, September 8. The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) earned “Neutral” rating by Mizuho on Thursday, May 12. The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has “Outperform” rating given on Thursday, December 24 by Credit Suisse. As per Thursday, June 16, the company rating was upgraded by Mizuho. The firm has “Sell” rating by TheStreet given on Friday, October 16.

According to Zacks Investment Research, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas.”

More important recent Adamas Pharmaceuticals Inc (NASDAQ:ADMS) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on June 21, 2011, also Fool.com published article titled: “Why Adamas Pharmaceuticals Dropped 25.3% in February”, Fool.com published: “Here’s Why Adamas Pharmaceuticals’ Stock Soared Today” on December 23, 2015. More interesting news about Adamas Pharmaceuticals Inc (NASDAQ:ADMS) was released by: Seekingalpha.com and their article: “Invest In Adamas Pharmaceuticals For Its Parkinson’s Disease Candidate” with publication date: July 05, 2016.

ADMS Company Profile

Adamas Pharmaceuticals, Inc., incorporated on November 15, 2000, is a pharmaceutical company. The Firm is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). The Firm is engaged in modifying the pharmacokinetic profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. The Company’s segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The Firm has selected aminoadamantanes as its initial area of focus, which have the ability to modulate multiple neurotransmitter systems, which are the molecular pathways that control brain function.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment